PCI Biotech Holding Logo

PCI Biotech Holding

Biopharma firm evaluating its future after discontinuing its core technology development.

PCIB | OL

Overview

Corporate Details

ISIN(s):
NO0010405640
LEI:
5967007LIEEXZXFIGG77
Country:
Norway
Address:
Ullernchausséen 64, 0379 OSLO
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PCI Biotech Holding is a biopharmaceutical company that was focused on developing a proprietary photochemical technology platform. This platform was designed to enhance intracellular drug delivery for therapeutic applications, including immunotherapy and dermatology, and to advance the bioprocessing and manufacturing of viral vectors for gene therapy. In August 2025, the company announced the discontinuation of its core technology development. Consequently, PCI Biotech is currently evaluating its future operations and strategic direction.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-23 10:35
Business and Financial Review
PCI Biotech update
English 3.6 KB
2025-09-25 15:36
Business and Financial Review
PCI Biotech update on future operations
English 3.6 KB
2025-08-26 16:14
Report Publication Announcement
PCI Biotech: Invitation to first half 2025 results presentation and corporate u…
English 2.3 KB
2025-08-22 14:15
Major Shareholding Notification
Flaggemelding
Norwegian 411 bytes
2025-08-22 11:09
Major Shareholding Notification
Flaggemelding
Norwegian 451 bytes
2025-08-18 20:39
Regulatory Filings
PCI Biotech announces discontinuation of development of the PCL technology and …
English 3.4 KB
2025-05-22 09:45
AGM Information
PCI Biotech: Minutes of Annual General Meeting 2025
Norwegian 449.8 KB
2025-05-22 09:45
AGM Information
PCI Biotech: Minutes of Annual General Meeting 2025
English 866 bytes
2025-05-20 20:08
Declaration of Voting Results & Voting Rights Announcements
PCI BIotech: Disclosure of voting rights for Chair of the Board
English 1.2 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
Norwegian 188.6 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
Norwegian 146.9 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 167.8 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 208.0 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 977 bytes
2025-04-24 15:30
Annual Report (ESEF)
PCI Biotech Holding ASA: Annual Report 2024
English 5.4 MB

Automate Your Workflow. Get a real-time feed of all PCI Biotech Holding filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PCI Biotech Holding

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PCI Biotech Holding via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060

Talk to a Data Expert

Have a question? We'll get back to you promptly.